Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab)
Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia and Xgeva, respectively, have also met their primary endpoint
Alvotech expects to file marketing applications for AVT03 later this year for major global markets
July 02, 2024 -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of bio